213
Views
10
CrossRef citations to date
0
Altmetric
Drug Evaluation

Topiramate for migraine prophylaxis

Pages 2811-2823 | Published online: 24 Oct 2007

Bibliography

  • STEINER TJ, SCHAR I, STEWART WF, KOLODNER K, LIBERMAN J, LIPTON RB: The prevalence and disability burden of adult migraine in England and their relationships to age, gender and ethnicity. Cephalalgia (2003) 23:519-527.
  • LIPTON RB, STEWART WF: The epidemiology of migraine. Eur. Neurol. (1994) 34(Suppl. 2):6-11.
  • STOVENER LJ, HAGEN K, JENSEN R et al.: The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia (2007) 27:193-210.
  • HEADACHE CLASSIFICATION SUBCOMMITTEE OF THE INTERNATIONAL HEADACHE SOCIETY: The International Classification of Headache Disorders. 2nd Edition. Cephalalgia (2004) 24(Suppl. 1):94-101.
  • HEADACHE CLASSIFICATION SUBCOMMITTEE OF THE INTERNATIONAL HEADACHE SOCIETY: New appendix criteria open for a broader concept of chronic migraine. Cephalalgia (2006) 26:742-746.
  • SILBERSTEIN SD, GOADSBY PJ: Migraine: preventative treatment. Cephalalgia (2002) 22:491-512.
  • WHITE HS: Molecular pharmacology of topiramate: managing seizures and preventing migraine. Headache (2005) 45(Suppl. 1):S48-S56.
  • GOADSBY PJ: Migraine pathophysiology. Headache (2005) 45(Suppl. 1):S14-S24.
  • CUTRER FM: Antiepileptic drugs: How they work in headache. Headache (2001) 41(Suppl. 1):S3-S10.
  • DURHAM PL, NIEMANN C, CADY R: Repression of stimulated calcitonin gene related peptide secretion by topiramate. Headache (2006) 46:1291-1295.
  • SHANK RP, GARDOCKI JF, STREETER AJ, MARYNOFF BE: An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics and mechanism of action. Epilepsia (2000) 41(Suppl. 1):S3-S9.
  • STORER RJ, GOADSBY PJ: Topiramate inhibits trigeminovascular neurones in the cat. Cephalalgia (2004) 24:1049-1056.
  • British National Formulary 53 March 2007. Appendix 1: Interactions: 745.
  • DOOSE DR, WANG SS, PADMANABHAN M, SCHWABE S, JACOBS D, BIALER M: Effect of topiramate or carbamazepine on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl oestradiol in healthy obese and non-obese female subjects. Epilepsia (2003) 44:540-549.
  • ROSENFELD WE, DOOSE DR, WALKER SA, NAYAK RK: Effect of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl oestradiol in patients with epilepsy. Epilepsia (1997) 38:317-323.
  • Faculty of family planning and reproductive health care, clinical effectiveness unit: Drug interactions with hormonal contraception. J. Fam. Plann. Reprod. Health Care (2005) 31:139-151.
  • MARTINEZ HR, LONDONO O, CANTU-MARTINEZ L, DEL CARMEN TARIN L, CASTILLO C: Topiramate as an adjunctive treatment in migraine prophylaxis. Headache (2003) 43:1080-1084.
  • MATHEW NT, KAILSASAM J, FISCHER A: Prophylaxis of migraine with topiramate: a retrospective analysis. Cephalalgia (2001) 22:370 (Abstract).
  • SHUAIB A, AHME F, MURATOGLU M, KOCHANSKI P: Topiramate in migraine prophylaxis: a pilot study. Cepahalalgia (1999) 19(4):379-380 (Abstract).
  • VON SEGGERN RL, MANNIX LK, ADELMAN JU: Efficacy of topiramate in migraine prophylaxis: a retrospective chart analysis. Headache (2002) 42:804-809.
  • YOUNG WB, HOPKINS MM, SCHECTER AL, SILBERSTEIN SD: Topiramate: a case series study in migraine prophylaxis. Cephalalgia (2002) 22:659-663.
  • EDWARDS KR, GLANTZ MJ, NORTON JA, CROSS N: Prophylactic treatment of episodic migraine with topiramate: a double-blind placebo-controlled trial in 30 patients. Cephalalgia (2000) 20:316.
  • POTTER DL, HART DE, CALDER CS, STOREY JR: A double-blind randomised, placebo-controlled study of topiramate in the prophylactic treatment of migraine with and without aura. Cephalalgia (2000) 20:305.
  • STOREY JR, CALDER CS, HART DE, POTTER DL: Topiramate in migraine prevention: a double blind placebo controlled study. Headache (2001) 41:968-975.
  • SILBERSTEIN SD, NETO W, SCHMITT J, JACOBS D: Topiramate in migraine prevention. Results of a large controlled trial. Arch. Neurol. (2004) 61:490-495.
  • BRANDES JL, SAPER JR, DIAMOND M et al.: Topiramate for migraine prophylaxis. JAMA (2004) 291:965-973.
  • DIENER HC, TFELT-HANSEN P, DAHLOF C et al.: Topiramate in migraine prophylaxis. Results from a placebo-controlled trial with propranolol as an active control. J. Neurol. (2004) 251:943-950.
  • BUSSONE G, DIENER HC, PFEIL J, SCHWALEN S: Topiramate 100 mg/day in migraine prevention: a pooled analysis of double-blind randomised controlled trials. Int. J. Clin. Pract. (2005) 59(8):961-968.
  • SILBERSTEIN SD: Topiramate in migraine prevention. Headache (2005) 45(Suppl. 1):S57-S65.
  • MATHEW NT, SAPER JR, SILBERSTEIN SD et al.: Migraine prophylaxis with divalproex. Arch. Neurol. (1995) 52:281-286.
  • KLAPPER J: Divalproex sodium in migraine prophylaxis: a dose controlled study. Cephalalgia (1997) 17:103-108.
  • FREITAG J: A randomised trial of divalproex sodium extended release tablets in migraine prophylaxis. Neurology (2002) 58:1652-1659.
  • MATHEW NT, RAPOPORT A, SAPER J et al.: Efficacy of gabapentin in migraine prophylaxis. Headache (2001) 41:119-128.
  • RAPOPORT A, MAUSKOP A, DIENER HC, SCHLEN S, PFEIL J: Long-term migraine prevention with topiramate: open-label extension of pivotal trials. Headache (2006) 46:1151-1160.
  • BARTOLINI M, SILVESTRINI M, TAFFI R et al.: Efficacy of topiramate and valproate in chronic migraine. Clin. Neuropharmacol. (2005) 28(6):277-279.
  • DIENER H-C, BUSSONE G, VAN OENE JC, LAHAYE M, SCHWALEN S, GOADSBY PJ ON BEHALF OF TOPMAT-MIG-201 (TOP-CHROME) STUDY GROUP: Topiramate reduces headache days in chronic migraine: a randomised, double-blind, placebo-controlled study. Cephalalgia (2007) 27:814-823.
  • SILBERSTEIN S, LIPTON RB, DODICK DW et al.: Efficacy and safety of topiramate for the treatment of chronic migraine: a randomised double blind placebo controlled trial. Headache (2007) 47:170-180.
  • ROTHROCK JF, PARADA VA, DRINKARD R, ZWEIFLER RM, KEY KF: Predictors of a negative response to topiramate therapy in patients with chronic migraine. Headache (2005) 45:932-935.
  • LIMMROTH V, BIONDI D, PFEIL J, SCHWALEN S: Topiramate in patients with episodic migraine: reducing the risk for chronic forms of headache. Headache (2007) 47:13-21.
  • HERSHEY AD, POWERS SW, VOCKELL AL, LECATES S, KABBOUCHE M: Effectiveness of topiramate in the prevention of headaches in childhood. Headache (2002) 42:810-818.
  • WINNER P, PEARLMAN EM, LINDER SL et al.: Topiramate for migraine prevention in children: a randomised, double-blind placebo-controlled trial. Headache (2005) 45:1304-1312.
  • WINNER P, GENDOLLA A, STAYER C et al.: Topiramate for migraine prevention in adolescents: a pooled analysis of efficacy and safety. Headache (2006) 46:1503-1510.
  • FRARE M, AXIA G, BATTISTELLA A: Quality of Life, coping strategies, and family routines in children with headache. Headache (2002) 42:953-962.
  • WINNER P, WASIEWSKI W, GLADSTEIN J, LINDER S: Multicentre prospective evaluation of proposed paediatric migraine revisions to the IHS criteria. Headache (1997) 37:545-548.
  • D'AMICO D, SOLARI A, USAI S et al.: Improvement in quality of life and activity limitations in migraine patients after prophylaxis. A prospective longitudinal multicentre study. Cephalalgia (2006) 26:691-696.
  • ADELMAN JU, ADELMAN LC, VON SEGGERN R: Cost-effectiveness of AED in migraine prophylaxis. Headache (2002) 42:978-983.
  • BROWN JS, PAPADOPOULOS G, NEUMANN PJ, FRIEDMAN M, MILLER J: Cost-effectiveness of topiramate in migraine prevention: results from a pharmacoeconomic model of topiramate treatment. Headache (2005) 45:1012-1022.
  • BROWN JS, PAPADOPOULOS G, NEUMAN PJ, PRICE M, FRIEDMAN M, MENZIN J: Cost-effectiveness of migraine prevention: the case in the UK. Cephalalgia (2006) 26:1473-1482.
  • SILBERSTEIN SD, LODER E, FORDE G, PAPADOLPOULOS G, FAIRCLOUGH D, GREENBERG S: The impact of migraine on daily activities: effect of topiramate compared to placebo. Curr. Med. Res. Opin. (2006) 22(8):1021-1029.
  • DIAMOND M, DAHLOF C, PAPADOPOULOS G, NETO A, WU S-C: Topiramate improves health-related quality of life when used to prevent migraine. Headache (2005) 45:1023-1030.
  • SILBERSTEIN SD, FELIU AL, RUPNOW MF, BLOUNT A, BOCCUZZI SJ: Topiramate in migraine prophylaxis: long-term impact on resource utilisation and cost. Headache (2007) 47:500-510.
  • BRANDES JL: Practical use of topiramate for migraine prevention. Headache (2005) 45(Suppl. 1):S66-S73.
  • LODER E, BIONDI D: General principles of migraine management: the changing role of prevention. Headache (2005) 45(Suppl. 1):S33-S47.

Websites

  • http://www.americanheadachesociety.org; http://www.neurology.org Ramadan NM, Silberstein SD, Freitag FG, Gilbert TT, Frishberg BM: Evidence based guidelines for migraine headache in the primary care setting: pharmacological management for the prevention of migraine. Neurology (2000) 55:754-762. (Accessed July 2007).
  • http://www.bash.org.uk Steiner TJ, MacGregor EA, Davies PTG: Guidelines for All healthcare professionals in the diagnosis and management of migraine, tension-type, cluster and medication-overuse headache. (Accessed July 2007).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.